Please login to the form below

non-Hodgkin's lymphoma

This page shows the latest non-Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

BeiGene bags FDA approval for first product Brukinsa in lymphoma

MCL is an aggressive type of non-Hodgkin’s lymphoma (NHL) for which Brukinsa also claimed a breakthrough designation from the FDA earlier this year. ... BeiGene is also developing PD-1 inhibitor tislelizumab – which has been filed for approval in

Latest news

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

The formulation – known as CC-486 – is an orally-active version of Vidaza, Celgene’s already-marketed azacitidine product which is administered intravenously. ... dosing. It’s also testing the drug in MDS, non-Hodgkin’s lymphoma (NHL) and other
Gracell reports impressive data with one-day CAR-T for leukaemia

Kymriah is approved for B-ALL as well as diffuse large B-cell lymphoma (DLBCL) – a form of non-Hodgkin’s lymphoma – and made just over $100m in sales in the ... Meanwhile, Gilead reported $216m in first-half sales from DLBCL and another NHL variant
BeiGene gets speedy US review for lymphoma drug zanubrutinib

The US regulator awarded the status for zanubrutinib as a second-line treatment for mantle cell lymphoma (MCL), an aggressive type of non-Hodgkin’s lymphoma for which the drug also ... In addition to zanubrutinib, BeiGene is also developing PD-1
Chi-Med cues up two more regulatory filings in cancer

It’s early take-up is already outstripping that of other VEGF inhibitors at this early stage, according to the biotech. ... Following after its first three drugs are potential first-in-class selective Syk inhibitor HMPL-523, in phase 1 testing for
Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

cancer, multiple myeloma, Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. ... and Merck’s Bavencio, and far behind MSD’s class leader Keytruda, expected to hit $14.5bn that year.

More from news
Approximately 15 fully matching, plus 118 partially matching documents found.

Latest Intelligence

Pharma deals during October 2014

Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.
Interview: Kay Drake and Naoki Okamura, Astellas

The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca. Immunogen has appointed Dr Charles Morris as the company's chief development officer. ... cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
Therapy Watch expands its oncology portfolio

Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
Oncology drugs under AMNOG

Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... against ‘treatment of physician’s